Abbott Australasia Pty Ltd

18 PBAC submissions on file, active 2005–2023. 44% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Adalimumab
  Rheumatology · Recommended with restriction · 2024other sponsor
• Paricalcitol
  Endocrinology · Not recommended · 2011—
• Sibutramine hydrochloride
  Endocrinology · Not recommended · 2008—
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids
  Metabolic · Recommended with restriction · 2023—
• Levodopa with carbidopa
  Neurology · Recommended with restriction · 2016other sponsor
• Omega-3-acid ethyl esters
  Cardiovascular · Not recommended · 2010—
• Trandolapril with verapamil
  Cardiovascular · Not recommended · 2005—
• Trandolapril with verapamil hydrochloride-sr
  Cardiovascular · Recommended with restriction · 2006—

Therapy area mix

Activity by year

2005 (1) · 2006 (5) · 2007 (2) · 2008 (3) · 2009 (2) · 2010 (3) · 2011 (1) · 2023 (1)

Rejection patterns

Across 10 Not recommended decisions on file.

• 3×uncertain cost-effectiveness
• 1×Lack of concordance between submission and proposed PBS population
• 1×uncertain clinical superiority over calcitriol based on non-randomised observational studies
• 1×most evidence from IV paricalcitol while oral formulation requested
• 1×no direct head-to-head comparison of oral paricalcitol versus oral calcitriol